Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Lipid Res ; 61(1): 45-53, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31604806

RESUMO

Elevated circulating levels of ceramides (Cers) are associated with increased risk of cardiometabolic diseases, and Cers may play a causative role in metabolic dysfunction that precedes cardiac events, such as mortality as a result of coronary artery disease. Although the mechanisms involved are likely complex, these associations suggest that lowering circulating Cer levels could be protective against cardiovascular diseases. Conversely, dietary fibers, such as inulin, have been reported to promote cardiovascular and metabolic health. However, the mechanisms involved in these protective processes also are not well understood. We studied the effects of inulin on lipid metabolism with a model of atherosclerosis in LDL receptor-deficient mice using lipidomics and transcriptomics. Plasma and tissues were collected at 10 days and/or 12 weeks after feeding mice an atherogenic diet supplemented with inulin or cellulose (control). Compared with controls, inulin-fed mice displayed a decreased C16:0/C24:0 plasma Cer ratio and lower levels of circulating Cers associated with VLDL and LDL. Liver transcriptomic analysis revealed that Smpd3, a gene that encodes neutral SMase (NSMase), was downregulated by 2-fold in inulin-fed mice. Hepatic NSMase activity was 3-fold lower in inulin-fed mice than in controls. Furthermore, liver redox status and compositions of phosphatidylserine and FFA species, the major factors that determine NSMase activity, were also modified by inulin. Taken together, these results showed that, in mice, inulin can decrease plasma Cer levels through reductions in NSMase expression and activity, suggesting a mechanism by which fiber could reduce cardiometabolic disease risk.


Assuntos
Ceramidas/antagonistas & inibidores , Inulina/farmacologia , Esfingomielina Fosfodiesterase/antagonistas & inibidores , Animais , Ceramidas/sangue , Biologia Computacional , Suplementos Nutricionais , Regulação para Baixo/efeitos dos fármacos , Inulina/administração & dosagem , Lipidômica , Masculino , Camundongos , Camundongos Knockout , Receptores de LDL/deficiência , Receptores de LDL/metabolismo , Esfingomielina Fosfodiesterase/genética , Esfingomielina Fosfodiesterase/metabolismo
2.
Front Immunol ; 11: 620348, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-33633739

RESUMO

Alzheimer's disease (AD) is the leading cause of dementia worldwide giving rise to devastating forms of cognitive decline, which impacts patients' lives and that of their proxies. Pathologically, AD is characterized by extracellular amyloid deposition, neurofibrillary tangles and chronic neuroinflammation. To date, there is no cure that prevents progression of AD. In this review, we elaborate on how bioactive lipids, including sphingolipids (SL) and specialized pro-resolving lipid mediators (SPM), affect ongoing neuroinflammatory processes during AD and how we may exploit them for the development of new biomarker panels and/or therapies. In particular, we here describe how SPM and SL metabolism, ranging from ω-3/6 polyunsaturated fatty acids and their metabolites to ceramides and sphingosine-1-phosphate, initiates pro- and anti-inflammatory signaling cascades in the central nervous system (CNS) and what changes occur therein during AD pathology. Finally, we discuss novel therapeutic approaches to resolve chronic neuroinflammation in AD by modulating the SPM and SL pathways.


Assuntos
Doença de Alzheimer/metabolismo , Ácidos Graxos Ômega-3/fisiologia , Ácidos Graxos Ômega-6/fisiologia , Esfingolipídeos/fisiologia , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/patologia , Animais , Sistema Nervoso Central/metabolismo , Ceramidas/antagonistas & inibidores , Ceramidas/fisiologia , Modelos Animais de Doenças , Ácidos Graxos Insaturados/metabolismo , Previsões , Humanos , Inflamação , Lipoxigenases/metabolismo , Lisofosfolipídeos/fisiologia , Camundongos , Microglia/patologia , Modelos Biológicos , Prostaglandina-Endoperóxido Sintases/metabolismo , Receptores de Reconhecimento de Padrão/fisiologia , Esfingosina/análogos & derivados , Esfingosina/fisiologia , Moduladores do Receptor de Esfingosina 1 Fosfato/uso terapêutico
3.
Anat Rec (Hoboken) ; 300(12): 2220-2232, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28806500

RESUMO

Neuronal damage in primary auditory cortex (A1) underlies complex manifestations of noise exposure, prevention of which is critical for health maintenance. Acid sphingomyelinase (ASM) catalyzes generation of ceramide (Cer) which if over-activated mediates neuronal disorders in various diseases. Tricyclic antidepressants (TCAs), by restraining ASM/Cer, benefits multiple neuronal anomalies, so we aimed to elucidate the effect of TCA on noise induced hearing loss and auditory cortex derangement, unraveling mechanism involved. The mice were exposed to noise with frequencies of 20-20 KHz and intensity of 95 dB. Doxepin hydrochloride (DOX), a kind of TCAs, was given intragastrically by 5 mg kg-1  days-1 . Morphology of neurons was examined using hematoxylin-eosin (HE) and Nissl staining. Apoptosis was assayed through transferase-mediated dUTP nick end labeling (TUNEL). The content of ASM, Cer or acid ceramidase (AC) was detected by western blot and immunohistochemistry analysis. We demonstrated intense, broad band noise caused upward shift of auditory brainstem response (ABR) threshold to sound over frequencies 4-32 KHz, with prominent morphologic changes and enhanced apoptosis in neurons of primary auditory cortex (A1) (P < 0.05). DOX partly restored noise-caused hearing loss alleviating morphologic changes or apoptosis remarkably (P < 0.05). Both ASM and Cer abundance were elevated significantly by noise which was reversed upon DOX treatment (P < 0.05), but neither noise nor DOX altered AC content. DOX had no influence on hearing, neuronal morphology or ASM/Cer in control mice. Our result suggests DOX palliates noise induced hearing loss and neuronal damage in auditory cortex by correcting over-activation of ASM/Cer without hampering intrinsic behavior of it. Anat Rec, 300:2220-2232, 2017. © 2017 Wiley Periodicals, Inc.


Assuntos
Córtex Auditivo/metabolismo , Ceramidas/metabolismo , Doxepina/farmacologia , Perda Auditiva Provocada por Ruído/metabolismo , Ruído/efeitos adversos , Esfingomielina Fosfodiesterase/metabolismo , Estimulação Acústica/efeitos adversos , Animais , Antidepressivos Tricíclicos/farmacologia , Antidepressivos Tricíclicos/uso terapêutico , Córtex Auditivo/efeitos dos fármacos , Córtex Auditivo/patologia , Ceramidas/antagonistas & inibidores , Doxepina/uso terapêutico , Perda Auditiva Provocada por Ruído/tratamento farmacológico , Perda Auditiva Provocada por Ruído/patologia , Masculino , Camundongos , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Neurônios/patologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/fisiologia , Esfingomielina Fosfodiesterase/antagonistas & inibidores
4.
Basic Res Cardiol ; 111(2): 12, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26786259

RESUMO

The injury caused by myocardial reperfusion after ischemia can be contained by interventions aimed at reducing the inflammation and the oxidative stress that underlie exacerbation of tissue damage. Sphingolipids are a class of structural and signaling lipid molecules; among them, the inflammation mediator ceramide accumulates in the myocardium upon ischemia/reperfusion. Here, we show that, after transient coronary occlusion in mice, an increased de novo ceramide synthesis takes place at reperfusion in the ischemic area surrounding necrosis (area at risk). This correlates with the enhanced expression of the first and rate-limiting enzyme of the de novo pathway, serine palmitoyltransferase (SPT). The intraventricular administration at reperfusion of myriocin, an inhibitor of SPT, significantly protected the area at risk from damage, reducing the infarcted area by 40.9 % relative to controls not treated with the drug. In the area at risk, myriocin downregulated ceramide, reduced the content in other mediators of inflammation and reactive oxygen species, and activated the Nrf2-HO1 cytoprotective response. We conclude that an enhanced ceramide synthesis takes part in ischemia/reperfusion injury and that myriocin treatment can be proposed as a strategy for myocardial pharmacological postconditioning.


Assuntos
Ceramidas/antagonistas & inibidores , Ácidos Graxos Monoinsaturados/uso terapêutico , Pós-Condicionamento Isquêmico/métodos , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Animais , Ceramidas/biossíntese , Avaliação Pré-Clínica de Medicamentos , Ácidos Graxos Monoinsaturados/farmacologia , Heme Oxigenase-1/metabolismo , Masculino , Camundongos Endogâmicos C57BL , Traumatismo por Reperfusão Miocárdica/metabolismo , Traumatismo por Reperfusão Miocárdica/patologia , Miocárdio/patologia , Fator 2 Relacionado a NF-E2/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo
5.
Biosci Biotechnol Biochem ; 77(2): 375-7, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23391909

RESUMO

Cell injury associated with reactive oxygen species (ROS) has been reported in various muscular disorders. We found that a Cichorium intybus (Cii) extract reduced H(2)O(2)-induced viability loss in C2C12 myoblasts, inhibited oxidative stress-induced apoptosis and increased intracellular heat shock protein 70 (Hsp 70) expression. Cii also inhibited the level of intracellular ceramide. These results indicate that Cii may prevent skeletal muscle atrophy by inducing the expression of Hsp 70 and inhibiting the level of ceramide.


Assuntos
Antioxidantes/farmacologia , Cichorium intybus/química , Mioblastos/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Extratos Vegetais/farmacologia , Raízes de Plantas/química , Acetilcisteína/farmacologia , Animais , Antioxidantes/isolamento & purificação , Apoptose/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Ceramidas/antagonistas & inibidores , Ceramidas/biossíntese , Expressão Gênica/efeitos dos fármacos , Proteínas de Choque Térmico HSP70/genética , Proteínas de Choque Térmico HSP70/metabolismo , Peróxido de Hidrogênio/farmacologia , Camundongos , Mioblastos/citologia , Mioblastos/metabolismo , Extratos Vegetais/isolamento & purificação , Espécies Reativas de Oxigênio/antagonistas & inibidores , Espécies Reativas de Oxigênio/metabolismo
6.
J Clin Invest ; 122(5): 1786-90, 2012 May.
Artigo em Inglês | MEDLINE | ID: mdl-22466649

RESUMO

Radiation gastrointestinal (GI) syndrome is a major lethal toxicity that may occur after a radiation/nuclear incident. Currently, there are no prophylactic countermeasures against radiation GI syndrome lethality for first responders, military personnel, or remediation workers entering a contaminated area. The pathophysiology of this syndrome requires depletion of stem cell clonogens (SCCs) within the crypts of Lieberkühn, which are a subset of cells necessary for postinjury regeneration of gut epithelium. Recent evidence indicates that SCC depletion is not exclusively a result of DNA damage but is critically coupled to ceramide-induced endothelial cell apoptosis within the mucosal microvascular network. Here we show that ceramide generated on the surface of endothelium coalesces to form ceramide-rich platforms that transmit an apoptotic signal. Moreover, we report the generation of 2A2, an anti-ceramide monoclonal antibody that binds to ceramide to prevent platform formation on the surface of irradiated endothelial cells of the murine GI tract. Consequently, we found that 2A2 protected against endothelial apoptosis in the small intestinal lamina propria and facilitated recovery of crypt SCCs, preventing the death of mice from radiation GI syndrome after high radiation doses. As such, we suggest that 2A2 represents a prototype of a new class of anti-ceramide therapeutics and an effective countermeasure against radiation GI syndrome mortality.


Assuntos
Anticorpos Monoclonais Murinos/farmacologia , Anticorpos Neutralizantes/farmacologia , Ceramidas/antagonistas & inibidores , Gastroenteropatias/prevenção & controle , Lesões Experimentais por Radiação/prevenção & controle , Animais , Anticorpos Monoclonais Murinos/uso terapêutico , Anticorpos Neutralizantes/uso terapêutico , Aorta/citologia , Apoptose/efeitos da radiação , Bovinos , Células Cultivadas , Ceramidas/imunologia , Ceramidas/metabolismo , Avaliação Pré-Clínica de Medicamentos , Células Endoteliais/enzimologia , Células Endoteliais/metabolismo , Células Endoteliais/efeitos da radiação , Indução Enzimática/efeitos da radiação , Gastroenteropatias/patologia , Humanos , Mucosa Intestinal/efeitos dos fármacos , Mucosa Intestinal/patologia , Mucosa Intestinal/efeitos da radiação , Microdomínios da Membrana/metabolismo , Microdomínios da Membrana/efeitos da radiação , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Lesões Experimentais por Radiação/patologia , Esfingomielina Fosfodiesterase/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA